Status
Conditions
Treatments
About
This is a prospective, multi-site, safety and feasibility study of the SalutarisMD SMD-DA system for retrobulbar minimally invasive episcleral brachytherapy device in patients receiving and not responding to anti-VEGF therapy for nAMD. The trial will be open label and non-randomized. The study intervention is a one-time intervention and requires no alteration to the standard of care during the follow-up period.
Full description
Subjects will receive a single brachytherapy treatment and 36 months of follow-up.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
11 participants in 1 patient group
Loading...
Central trial contact
Hailey Davenport, BS; Mary Drew, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal